JP2017515841A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515841A5 JP2017515841A5 JP2016567413A JP2016567413A JP2017515841A5 JP 2017515841 A5 JP2017515841 A5 JP 2017515841A5 JP 2016567413 A JP2016567413 A JP 2016567413A JP 2016567413 A JP2016567413 A JP 2016567413A JP 2017515841 A5 JP2017515841 A5 JP 2017515841A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- taa
- antagonist
- immunogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 47
- 239000000427 antigen Substances 0.000 claims description 27
- 102000036639 antigens Human genes 0.000 claims description 27
- 108091007433 antigens Proteins 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 239000005557 antagonist Substances 0.000 claims description 21
- 229940123803 TIM3 antagonist Drugs 0.000 claims description 20
- 241000700629 Orthopoxvirus Species 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 12
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 12
- 241000700663 Avipoxvirus Species 0.000 claims description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 11
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 9
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 9
- 239000000556 agonist Substances 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 241000700618 Vaccinia virus Species 0.000 claims description 7
- 102000000763 Survivin Human genes 0.000 claims description 6
- 108010002687 Survivin Proteins 0.000 claims description 6
- 241000700662 Fowlpox virus Species 0.000 claims description 5
- 101100262328 Mus musculus Dct gene Proteins 0.000 claims description 5
- 101100154912 Mus musculus Tyrp1 gene Proteins 0.000 claims description 5
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 4
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 claims description 3
- 102000013563 Acid Phosphatase Human genes 0.000 claims description 3
- 108010051457 Acid Phosphatase Proteins 0.000 claims description 3
- 229940032310 PROSTVAC vaccine Drugs 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 208000007089 vaccinia Diseases 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims 24
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 8
- 102100034256 Mucin-1 Human genes 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 12
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 12
- 229940045513 CTLA4 antagonist Drugs 0.000 description 10
- 102000017578 LAG3 Human genes 0.000 description 8
- 101150030213 Lag3 gene Proteins 0.000 description 8
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 7
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 7
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 7
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 6
- 229940126546 immune checkpoint molecule Drugs 0.000 description 6
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 5
- 229940124060 PD-1 antagonist Drugs 0.000 description 3
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- 101000796203 Homo sapiens L-dopachrome tautomerase Proteins 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 102000007298 Mucin-1 Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020072789A JP7368305B2 (ja) | 2014-05-13 | 2020-04-15 | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461992771P | 2014-05-13 | 2014-05-13 | |
| US61/992,771 | 2014-05-13 | ||
| PCT/US2015/029885 WO2015175340A1 (en) | 2014-05-13 | 2015-05-08 | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020072789A Division JP7368305B2 (ja) | 2014-05-13 | 2020-04-15 | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017515841A JP2017515841A (ja) | 2017-06-15 |
| JP2017515841A5 true JP2017515841A5 (enExample) | 2018-06-07 |
Family
ID=53264790
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567413A Pending JP2017515841A (ja) | 2014-05-13 | 2015-05-08 | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ−３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
| JP2020072789A Active JP7368305B2 (ja) | 2014-05-13 | 2020-04-15 | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020072789A Active JP7368305B2 (ja) | 2014-05-13 | 2020-04-15 | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3142689B1 (enExample) |
| JP (2) | JP2017515841A (enExample) |
| AU (1) | AU2015259516B2 (enExample) |
| CA (1) | CA2946606C (enExample) |
| DK (1) | DK3142689T3 (enExample) |
| ES (1) | ES2851451T3 (enExample) |
| IL (1) | IL248511B (enExample) |
| WO (1) | WO2015175340A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016115116A1 (en) | 2015-01-12 | 2016-07-21 | Geovax, Inc. | Compositions and methods for generating an immune response to a hemorrhagic fever virus |
| US12030942B2 (en) | 2015-10-02 | 2024-07-09 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
| EP3402802B1 (en) * | 2016-01-08 | 2023-04-12 | Geovax, Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
| BR112018015696A2 (pt) | 2016-02-03 | 2018-12-26 | Geovax Inc | composições e métodos para gerar uma resposta imune para um flavivírus |
| CN107281474A (zh) * | 2016-04-11 | 2017-10-24 | 中国科学院上海巴斯德研究所 | 增强抗肿瘤免疫反应的新型免疫策略和免疫组合物 |
| WO2017178493A1 (en) | 2016-04-12 | 2017-10-19 | Symphogen A/S | Anti-tim-3 antibodies and compositions |
| RS65007B1 (sr) | 2016-06-02 | 2024-01-31 | Ultimovacs Asa | Vakcina u kombinaciji sa inhibitorom imunološke kontrolne tačke za primenu u lečenju kancera |
| US20190248893A1 (en) | 2016-07-14 | 2019-08-15 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| WO2018140890A1 (en) * | 2017-01-29 | 2018-08-02 | Zequn Tang | Methods of immune modulation against foreign and/or auto antigens |
| UA129904C2 (uk) * | 2017-04-05 | 2025-09-10 | Ле Лаборатуар Сервьє | Комбінація антитіла до tim-3 й антитіла до pd-1 для лікування раку |
| US11052147B2 (en) | 2017-05-15 | 2021-07-06 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| WO2018210804A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| HUE065242T2 (hu) | 2017-05-30 | 2024-05-28 | Bristol Myers Squibb Co | LAG-3-pozitív tumorok kezelése |
| JP7334124B2 (ja) | 2017-06-21 | 2023-08-28 | トランジェーヌ | 個別化ワクチン |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| CN111918660A (zh) * | 2018-01-24 | 2020-11-10 | 复诺健生物科技加拿大有限公司 | 重组病毒疫苗 |
| CN111253485A (zh) * | 2018-11-30 | 2020-06-09 | 上海开拓者生物医药有限公司 | 抗人tim-3单克隆抗体及其应用 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CA3161800A1 (en) | 2019-11-18 | 2021-05-27 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| AU2021290177A1 (en) * | 2020-06-10 | 2023-01-19 | Bavarian Nordic A/S | A recombinant Modified Vaccinia Virus Ankara (MVA) vaccine against coronavirus disease |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| ATE151110T1 (de) | 1988-09-02 | 1997-04-15 | Protein Eng Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE363532T1 (de) | 1991-03-01 | 2007-06-15 | Dyax Corp | Verfahren zur herstellung bindender miniproteine |
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| JP3926839B2 (ja) | 1993-09-14 | 2007-06-06 | エピミューン，インコーポレイティド | 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変 |
| US6165460A (en) | 1995-07-10 | 2000-12-26 | Therion Biologics Corporation | Generation of immune responses to prostate-specific antigen (PSA) |
| JP4475683B2 (ja) | 1996-07-25 | 2010-06-09 | アメリカ合衆国 | 腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス |
| AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
| EP1012276A2 (en) | 1997-02-24 | 2000-06-28 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| US6756038B1 (en) | 1997-10-10 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Agonist and antagonist peptides of carcinoembryonic antigen (CEA) |
| CN1325115C (zh) | 1998-10-05 | 2007-07-11 | 法麦克萨有限公司 | Ctl表位和t辅助淋巴细胞表位在免疫接种中的应用 |
| KR100910297B1 (ko) | 2000-11-23 | 2009-08-03 | 버베리안 노딕 에이/에스 | 변형된 백시니아 앙카라 바이러스 변형체 |
| CA2468258C (en) | 2001-11-30 | 2011-10-11 | Jeffrey Schlom | Peptide agonists of prostate-specific antigen, and uses therefor |
| AU2004289368B2 (en) * | 2003-11-12 | 2010-08-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Custom vectors for treating and preventing pancreatic cancer |
| KR20070037570A (ko) * | 2004-03-24 | 2007-04-05 | 텔로스 파마슈티칼스 인코포레이티드 | 백신에 대한 면역반응을 향상시키는 보강제로서의 조성물및 이의 사용 방법 |
| KR101498834B1 (ko) * | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
| US20110059106A1 (en) * | 2008-01-29 | 2011-03-10 | Brigham And Women's Hospital, Inc. | Methods for modulating a population of myeloid-derived suppressor cells and uses thereof |
| CN104826106B (zh) | 2009-09-30 | 2019-01-11 | 斯隆凯特林防癌纪念中心 | 用于治疗癌症的组合免疫疗法 |
| JP5760796B2 (ja) | 2011-07-22 | 2015-08-12 | 富士通株式会社 | 冷却ユニット |
| US20140294765A1 (en) | 2012-06-21 | 2014-10-02 | Compugen Ltd. | Lsr antibodies, and uses thereof for treatment of cancer |
| US20150283220A1 (en) * | 2012-10-19 | 2015-10-08 | Bavarian Nordic, Inc. | Methods and compositions for the treatment of cancer |
-
2015
- 2015-05-08 EP EP15724454.2A patent/EP3142689B1/en active Active
- 2015-05-08 ES ES15724454T patent/ES2851451T3/es active Active
- 2015-05-08 CA CA2946606A patent/CA2946606C/en active Active
- 2015-05-08 IL IL248511A patent/IL248511B/en unknown
- 2015-05-08 JP JP2016567413A patent/JP2017515841A/ja active Pending
- 2015-05-08 DK DK15724454.2T patent/DK3142689T3/da active
- 2015-05-08 WO PCT/US2015/029885 patent/WO2015175340A1/en not_active Ceased
- 2015-05-08 AU AU2015259516A patent/AU2015259516B2/en active Active
-
2020
- 2020-04-15 JP JP2020072789A patent/JP7368305B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515841A5 (enExample) | ||
| JP2017515837A5 (enExample) | ||
| JP2016537417A5 (enExample) | ||
| DeMaria et al. | Cancer vaccines | |
| Yang et al. | DNA vaccine for cancer immunotherapy | |
| RU2016148311A (ru) | Комбинированная терапия для лечения рака с помощью рекомбинантного поксвируса, экспрессирующего опухолевый антиген, и антагониста или агониста молекулы иммунной контрольной точки | |
| JP7368305B2 (ja) | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 | |
| Gatti-Mays et al. | Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations | |
| RU2016122035A (ru) | Комбинированное лекарственное средство для лечения рака с использованием поксвируса, экспрессирующего опухолевый антиген, и антагониста и/или агониста ингибитора имунной контрольной точки | |
| Madan et al. | Clinical evaluation of TRICOM vector therapeutic cancer vaccines | |
| Milani et al. | Recent advances in the development of breast cancer vaccines | |
| JP2018522822A5 (enExample) | ||
| CA2665068A1 (en) | Methods for treating cancer with mva | |
| Chang et al. | Vaccinating against cancer: getting to prime time | |
| Nicolini et al. | The use of immunotherapy to treat metastatic breast cancer | |
| CN119770632A (zh) | 诱导免疫应答的组合物和方法 | |
| Zhang et al. | Management of castrate resistant prostate cancer—recent advances and optimal sequence of treatments | |
| Yarchoan et al. | 453 Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma | |
| JPWO2020104531A5 (enExample) | ||
| Kraynyak et al. | Tapping the potential of DNA delivery with electroporation for cancer immunotherapy | |
| JP6297641B2 (ja) | 愛玩動物の癌の補助治療としてのＨｅｒ２ＤＮＡワクチン | |
| US20110104101A1 (en) | Immunotherapy for Unresectable Pancreatic Cancer | |
| JPWO2021099586A5 (enExample) | ||
| Witt | Cripto-1: potential target for cancer immunotherapy?! | |
| Helwick | Breast Cancer Vaccines Moving Forward at a Fast Clip |